Report Summarizes Coagulation Modifiers Study Findings from University of Electronic Science and Technology of China [Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)].
In: Medical Devices & Surgical Technology Week, 2024-03-29, S. 1905-1905
serialPeriodical
Zugriff:
A recent study conducted by the University of Electronic Science and Technology of China has focused on the use of fondaparinux, a parenteral anticoagulant medicine, for the treatment of thromboembolic disease. The study aimed to consolidate evidence-based research on the drug and provide clinical suggestions for its optimal usage. The study resulted in 17 recommendations, including the use of fondaparinux for venous thromboembolism prevention and treatment, perioperative surgical prophylaxis, specific diseases, special populations, bleeding and overdose management. The researchers also highlighted the need for further investigation into the adverse events and safety profiles associated with the use of fondaparinux. [Extracted from the article]
Copyright of Medical Devices & Surgical Technology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Report Summarizes Coagulation Modifiers Study Findings from University of Electronic Science and Technology of China [Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)].
|
---|---|
Zeitschrift: | Medical Devices & Surgical Technology Week, 2024-03-29, S. 1905-1905 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1537-1409 (print) |
Schlagwort: |
|
Sonstiges: |
|